Diagnostic Center | June 14, 2024
Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Subscribe To Our Newsletter & Stay Updated
